Merck Acquires Verona Pharma in $10B Deal
Merck has agreed to acquire Verona Pharma in a deal valued at approximately $10 billion. The acquisition, approved by the High Court of Justice of England and Wales, is set to close on October 7, 2022.
The acquisition price is set at $107 per American Depository Share, with each one representing eight Verona ordinary shares. The deal will see Verona Pharma's shares cease trading on Monday, October 3, 2022. Leading this significant acquisition for Merck is Belén Garijo, the company's CEO.
The acquisition, valued at around $10 billion, is set to close on October 7, 2022, following approval from the High Court of Justice. Merck's CEO, Belén Garijo, is overseeing the deal, which will see Verona Pharma's shares delist on October 3, 2022.
